title: Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen.
abstract: In most studies, people who have not responded virologically to a protease inhibitor (PI)-containing regimen have tended to experience poor virologic responses to subsequent regimens. We describe the 2-year viral load, CD4 count, and clinical outcome of a multidrug regimen used in 60 people who had not responded virologically to a PI-containing regimen. At baseline, median CD4 count was 126/mm(3) (nadir 30/mm(3) ) and median viral load was 320,000 copies/mL. A median of five antiretroviral drugs had previously been used, of which a median of two were PIs. Of these patients, 16% had previously used another nonnucleoside reverse transcriptase inhibitor besides efavirenz. The multidrug regimen (median 5 drugs) started most commonly included efavirenz (100%), at least one PI (92%, usually indinavir/ritonavir), didanosine (78%), and hydroxyurea (74%). At year 2, 5 patients had died and 5 had no measure available. Nine patients developed a new AIDS event and 10 patients were known to have stopped all antiretroviral therapy. Thirty-one patients (52% of the whole group, 72% of those remaining on therapy with viral load value available) had viral load <50 copies/mL. Thus, a substantial proportion of patients who had failed to respond virologically to PI-containing regimens can achieve profound and sustained virologic suppression with a multidrug regimen.
authors.affiliation: Royal Free Centre for HIV Medicine, Royal Free & University College Medical School, London, United Kingdom. myoule@rfh1.demon.co.uk
authors.forename: Mike
authors.initials: M
authors.lastname: Youle
authors.forename: Mervyn
authors.initials: M
authors.lastname: Tyrer
authors.forename: Martin
authors.initials: M
authors.lastname: Fisher
authors.forename: Fiona
authors.initials: F
authors.lastname: Lampe
authors.forename: Deborah
authors.initials: D
authors.lastname: Wilson
authors.forename: Darren
authors.initials: D
authors.lastname: Ransom
authors.forename: Alister
authors.initials: A
authors.lastname: Story
authors.forename: Amanda
authors.initials: A
authors.lastname: Mocroft
authors.forename: Clive
authors.initials: C
authors.lastname: Loveday
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Johnson
authors.forename: Andrew N
authors.initials: AN
authors.lastname: Phillips
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017211:Treatment Failure; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors